Loading stock data…
EQ
$2.08+0.04 (+1.96%)
Market ClosedLast close May 1
Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Equillium, Inc. in the Healthcare sector is trading at $2.08. The stock is currently 23% below its 52-week high of $2.70, remaining 45.5% above its 200-day moving average. Technical signals show neutral RSI of 65 and bearish MACD signal, explaining why EQ maintains its current momentum and trend strength. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Overbought levels (RSI 65) — risk of consolidation or pullback
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$2.08
Potential Upside
5%
Whystock Fair Value$2.18
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need in the United States. Its lead product candidate is Itolizumab (EQ001...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$137.83M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.74
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-78.32%
Volume
Today's trading volume
145,621
Recent News
Here’s What Roth Capital Thinks of Equillium (EQ) Stock
Equillium, Inc. (NASDAQ:EQ) is one of the 10 Best High-Risk Penny Stocks to Buy Right Now. On March 13, Roth Capital analyst Adam Walsh initiated coverage of Equillium, Inc. (NASDAQ:EQ), assigning a Buy rating and a price target of $12. The firm’s assigned price target suggests a compelling 458% upside from the current levels. The […]
Equillium Conference: EQ504 Targets Ulcerative Colitis Ahead of Mid-Year Phase 1 Start
Executives from Equillium (NASDAQ:EQ) outlined the scientific rationale and near-term development plans for its lead program, EQ504, during a recent fireside chat focused on immunology and inflammatory bowel disease (IBD). Positioning EQ504 in ulcerative colitis Company representatives described ul
Trending tickers: Intel, Tilray, monday.com, Equillium and AMC
The latest investor updates on stocks that are trending on Tuesday
BC-Most Active Stocks
Gibo Holdings Ltd. 239,477,124 0.049
Spotlight On 3 Promising Penny Stocks With Over $20M Market Cap
As the U.S. markets react to recent economic uncertainties, including weak job reports and tariff concerns, investors are reassessing their strategies amid fluctuating indices. In this context, penny stocks—often perceived as remnants of a bygone era—continue to capture attention for their potential value and growth opportunities. Despite their small size or relative newness, these stocks can offer intriguing prospects when backed by solid financials.